Shares Outstanding (Quarterly) Chart

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 2010. Start Trial.
Date Value
June 30, 2026 51.10M
March 31, 2026 50.88M
December 31, 2025 50.41M
September 30, 2025 50.38M
June 30, 2025 49.89M
March 31, 2025 49.62M
December 31, 2024 49.11M
September 30, 2024 49.07M
June 30, 2024 48.46M
March 31, 2024 48.21M
December 31, 2023 47.65M
September 30, 2023 47.54M
June 30, 2023 46.95M
March 31, 2023 46.66M
December 31, 2022 41.18M
September 30, 2022 45.61M
June 30, 2022 45.27M
March 31, 2022 44.95M
December 31, 2021 40.09M
September 30, 2021 40.86M
June 30, 2021 40.73M
March 31, 2021 40.32M
December 31, 2020 40.09M
September 30, 2020 39.72M
June 30, 2020 39.63M
Date Value
March 31, 2020 39.32M
December 31, 2019 39.20M
September 30, 2019 38.94M
June 30, 2019 38.74M
March 31, 2019 38.57M
December 31, 2018 38.32M
September 30, 2018 38.13M
June 30, 2018 37.89M
March 31, 2018 37.76M
December 31, 2017 37.59M
September 30, 2017 37.38M
June 30, 2017 37.06M
March 31, 2017 36.96M
December 31, 2016 36.83M
September 30, 2016 32.50M
June 30, 2016 32.49M
March 31, 2016 32.49M
December 31, 2015 32.47M
September 30, 2015 32.42M
June 30, 2015 32.21M
March 31, 2015 32.09M
December 31, 2014 30.55M
September 30, 2014 30.12M
June 30, 2014 30.12M
March 31, 2014 30.12M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
Anika Therapeutics, Inc. 13.38M
Arcutis Biotherapeutics, Inc. 125.59M
ACADIA Pharmaceuticals, Inc. 172.13M
Alnylam Pharmaceuticals, Inc. 133.73M
Savara, Inc. 205.40M